EGFR mutations and treatment response in cancer

被引：0
|
作者：
Cottrell, Sally [1 ]
Butler, Rachel [1 ]
机构：
[1] Harvard Partners Ctr Genet & Genom, Mol Med Lab, Cambridge, MA 02139 USA
来源：
JOURNAL OF MEDICAL GENETICS | 2006年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
    Haber, D. A.
    Bell, D. W.
    Sordella, R.
    Kwak, E. L.
    Godin-Heymann, N.
    Sharma, S. V.
    Lynch, T. J.
    Settleman, J.
    Molecular Approaches to Controlling Cancer, 2005, 70 : 419 - 426
  • [2] Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
    Beth O. Van Emburgh
    Sabrina Arena
    Giulia Siravegna
    Luca Lazzari
    Giovanni Crisafulli
    Giorgio Corti
    Benedetta Mussolin
    Federica Baldi
    Michela Buscarino
    Alice Bartolini
    Emanuele Valtorta
    Joana Vidal
    Beatriz Bellosillo
    Giovanni Germano
    Filippo Pietrantonio
    Agostino Ponzetti
    Joan Albanell
    Salvatore Siena
    Andrea Sartore-Bianchi
    Federica Di Nicolantonio
    Clara Montagut
    Alberto Bardelli
    Nature Communications, 7
  • [3] Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
    van Emburgh, Beth O.
    Arena, Sabrina
    Siravegna, Giulia
    Lazzari, Luca
    Crisafulli, Giovanni
    Corti, Giorgio
    Mussolin, Benedetta
    Baldi, Federica
    Buscarino, Michela
    Bartolini, Alice
    Valtorta, Emanuele
    Vidal, Joana
    Bellosillo, Beatriz
    Germano, Giovanni
    Pietrantonio, Filippo
    Ponzetti, Agostino
    Albanell, Joan
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Di Nicolantonio, Federica
    Montagut, Clara
    Bardelli, Alberto
    NATURE COMMUNICATIONS, 2016, 7
  • [4] EGFR mutations predict lung-cancer response to gefitinib
    Bradbury, J
    LANCET ONCOLOGY, 2004, 5 (06): : 335 - 335
  • [5] The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer
    Lopez-Chavez, Ariel
    Carter, Corey A.
    Giaccone, Giuseppe
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (12) : 1305 - 1314
  • [6] The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer
    Karachaliou, Niki
    Angel Molina-Vila, Miguel
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 241 - 244
  • [7] Heterogeneity response to afatinib in gastric cancer patient with uncommon EGFR mutations
    Liu, Qin
    Wei, Jia
    Yang, Yang
    Wang, Yue
    Liu, Baorui
    Shao, Yang
    CANCER RESEARCH, 2019, 79 (13)
  • [8] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
    Paez, JG
    Jänne, PA
    Lee, JC
    Tracy, S
    Greulich, H
    Gabriel, S
    Herman, P
    Kaye, FJ
    Lindeman, N
    Boggon, TJ
    Naoki, K
    Sasaki, H
    Fujii, Y
    Eck, MJ
    Sellers, WR
    Johnson, BE
    Meyerson, M
    SCIENCE, 2004, 304 (5676) : 1497 - 1500
  • [9] Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations
    O'Sullivan, H. M.
    MacMahon, S.
    Cunningham, N.
    Farag, S.
    d'Arienzo, P. D.
    Milner-Watts, C.
    Tokaca, N.
    Davidson, M.
    Minchom, A.
    Bhosle, J.
    Yousaf, N.
    Cui, W.
    O'Brien, M.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S430 - S430
  • [10] EGFR Mutations and Lung Cancer
    Santos, Gilda da Cunha
    Shepherd, Frances A.
    Tsao, Ming Sound
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6, 2011, 6 : 49 - 69
12345